Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solar-Recur: Copper Cu 64 PSMA I&T PET/CT in Recurrent Prostate Cancer
NCT06235099Phase 3Completed
- Sponsor
- Curium
- Start
- Apr 2024
- Primary completion
- Feb 2025
- Modality
- Radiopharmaceutical, CA (Contrast Agent)
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of copper Cu 64 PSMA I&T in prostate cancer (PCa), sponsored by Curium. Primary endpoints: Patient-Level Correct Detection Rate at 4 hours and Region-Level Correct Localization Rate at 4 hours. Started Apr 2024; status: completed.
02
Drugs
copper Cu 64 PSMA I&T
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06235099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06235099.